A  ||| S:0 E:2 ||| DT
systematic  ||| S:2 E:13 ||| JJ
comparison  ||| S:13 E:24 ||| NN
of  ||| S:24 E:27 ||| IN
rheumatoid  ||| S:27 E:38 ||| JJ
arthritis  ||| S:38 E:48 ||| NN
and  ||| S:48 E:52 ||| CC
ankylosing  ||| S:52 E:63 ||| JJ
spondylitis ||| S:63 E:74 ||| NN
:  ||| S:74 E:76 ||| :
structural  ||| S:76 E:87 ||| JJ
outcomes  ||| S:87 E:96 ||| JJ
Rheumatoid  ||| S:96 E:107 ||| JJ
arthritis  ||| S:107 E:117 ||| NN
and  ||| S:117 E:121 ||| CC
ankylosing  ||| S:121 E:132 ||| JJ
spondylitis  ||| S:132 E:144 ||| NNS
are  ||| S:144 E:148 ||| VBP
both  ||| S:148 E:153 ||| DT
chronic  ||| S:153 E:161 ||| JJ
diseases  ||| S:161 E:170 ||| NNS
with  ||| S:170 E:175 ||| IN
inflammation  ||| S:175 E:188 ||| NN
as  ||| S:188 E:191 ||| IN
a  ||| S:191 E:193 ||| DT
hallmark ||| S:193 E:201 ||| NN
.  ||| S:201 E:203 ||| .
Both  ||| S:203 E:208 ||| DT
diseases  ||| S:208 E:217 ||| NNS
are  ||| S:217 E:221 ||| VBP
characterized  ||| S:221 E:235 ||| VBN
by  ||| S:235 E:238 ||| IN
structural  ||| S:238 E:249 ||| JJ
abnormalities  ||| S:249 E:263 ||| NN
of  ||| S:263 E:266 ||| IN
the  ||| S:266 E:270 ||| DT
peripheral  ||| S:270 E:281 ||| JJ
joints  ||| S:281 E:288 ||| NNS
( ||| S:288 E:289 ||| -LRB-
RA ||| S:289 E:291 ||| NNP
)  ||| S:291 E:293 ||| -RRB-
or  ||| S:293 E:296 ||| CC
the  ||| S:296 E:300 ||| DT
spine  ||| S:300 E:306 ||| NN
( ||| S:306 E:307 ||| -LRB-
AS ||| S:307 E:309 ||| NNP
)  ||| S:309 E:311 ||| -RRB-
that  ||| S:311 E:316 ||| WDT
can  ||| S:316 E:320 ||| MD
be  ||| S:320 E:323 ||| VB
visualized  ||| S:323 E:334 ||| VBN
on  ||| S:334 E:337 ||| IN
conventional  ||| S:337 E:350 ||| JJ
radiographs ||| S:350 E:361 ||| NN
.  ||| S:361 E:363 ||| .
RA  ||| S:363 E:366 ||| NNP
is  ||| S:366 E:369 ||| VBZ
associated  ||| S:369 E:380 ||| VBN
with  ||| S:380 E:385 ||| IN
destruction  ||| S:385 E:397 ||| NN
( ||| S:397 E:398 ||| -LRB-
erosions ||| S:398 E:406 ||| UH
,  ||| S:406 E:408 ||| ,
joint  ||| S:408 E:414 ||| JJ
space  ||| S:414 E:420 ||| NN
narrowing ||| S:420 E:429 ||| NN
)  ||| S:429 E:431 ||| -RRB-
whilst  ||| S:431 E:438 ||| VBZ
AS  ||| S:438 E:441 ||| NNP
is  ||| S:441 E:444 ||| VBZ
dominated  ||| S:444 E:454 ||| VBN
by  ||| S:454 E:457 ||| IN
bone  ||| S:457 E:462 ||| NN
formation  ||| S:462 E:472 ||| NN
( ||| S:472 E:473 ||| -LRB-
syndesmophytes ||| S:473 E:487 ||| LS
) ||| S:487 E:488 ||| -RRB-
.  ||| S:488 E:490 ||| .
The  ||| S:490 E:494 ||| DT
causative  ||| S:494 E:504 ||| JJ
relationship  ||| S:504 E:517 ||| NN
between  ||| S:517 E:525 ||| IN
inflammation  ||| S:525 E:538 ||| NN
and  ||| S:538 E:542 ||| CC
structural  ||| S:542 E:553 ||| JJ
damage  ||| S:553 E:560 ||| NN
in  ||| S:560 E:563 ||| IN
RA  ||| S:563 E:566 ||| NNP
is  ||| S:566 E:569 ||| VBZ
well  ||| S:569 E:574 ||| RB
established ||| S:574 E:585 ||| VBN
,  ||| S:585 E:587 ||| ,
whilst  ||| S:587 E:594 ||| VBG
this  ||| S:594 E:599 ||| DT
relation  ||| S:599 E:608 ||| NN
is  ||| S:608 E:611 ||| VBZ
largely  ||| S:611 E:619 ||| RB
unknown  ||| S:619 E:627 ||| JJ
but  ||| S:627 E:631 ||| CC
certainly  ||| S:631 E:641 ||| RB
less  ||| S:641 E:646 ||| RBR
strong  ||| S:646 E:653 ||| JJ
in  ||| S:653 E:656 ||| IN
AS ||| S:656 E:658 ||| NNP
.  ||| S:658 E:660 ||| .
Progression  ||| S:660 E:672 ||| NNP
of  ||| S:672 E:675 ||| IN
structural  ||| S:675 E:686 ||| JJ
damage  ||| S:686 E:693 ||| NN
in  ||| S:693 E:696 ||| IN
RA  ||| S:696 E:699 ||| NNP
is  ||| S:699 E:702 ||| VBZ
inhibited  ||| S:702 E:712 ||| VBN
by  ||| S:712 E:715 ||| IN
disease  ||| S:715 E:723 ||| NN
modifying  ||| S:723 E:733 ||| VBZ
anti-rheumatic  ||| S:733 E:748 ||| JJ
drugs  ||| S:748 E:754 ||| NNS
and  ||| S:754 E:758 ||| CC
especially  ||| S:758 E:769 ||| RB
by  ||| S:769 E:772 ||| IN
TNF-blockade ||| S:772 E:784 ||| NNP
,  ||| S:784 E:786 ||| ,
whilst  ||| S:786 E:793 ||| JJ
progression  ||| S:793 E:805 ||| NN
of  ||| S:805 E:808 ||| IN
structural  ||| S:808 E:819 ||| JJ
damage  ||| S:819 E:826 ||| NN
in  ||| S:826 E:829 ||| IN
AS  ||| S:829 E:832 ||| NNP
seems  ||| S:832 E:838 ||| VBZ
insensitive  ||| S:838 E:850 ||| VBN
to  ||| S:850 E:853 ||| TO
TNF-blockade  ||| S:853 E:866 ||| JJ
but  ||| S:866 E:870 ||| CC
sensitive  ||| S:870 E:880 ||| JJ
to  ||| S:880 E:883 ||| TO
non-steroidal  ||| S:883 E:897 ||| JJ
inflammatory  ||| S:897 E:910 ||| JJ
drugs.In  ||| S:910 E:919 ||| CD
this  ||| S:919 E:924 ||| DT
article ||| S:924 E:931 ||| NN
,  ||| S:931 E:933 ||| ,
similarities  ||| S:933 E:946 ||| NNS
and  ||| S:946 E:950 ||| CC
dissimilarities  ||| S:950 E:966 ||| NN
with  ||| S:966 E:971 ||| IN
respect  ||| S:971 E:979 ||| NN
to  ||| S:979 E:982 ||| TO
structural  ||| S:982 E:993 ||| JJ
damage  ||| S:993 E:1000 ||| NN
in  ||| S:1000 E:1003 ||| IN
RA  ||| S:1003 E:1006 ||| NNP
and  ||| S:1006 E:1010 ||| CC
AS  ||| S:1010 E:1013 ||| NNP
are  ||| S:1013 E:1017 ||| VBP
discussed  ||| S:1017 E:1027 ||| VBN
and  ||| S:1027 E:1031 ||| CC
set  ||| S:1031 E:1035 ||| VBN
against  ||| S:1035 E:1043 ||| IN
a  ||| S:1043 E:1045 ||| DT
background ||| S:1045 E:1055 ||| NN
.  ||| S:1055 E:1057 ||| .
